The Alfred Hospital in Melbourne, Australia has been selected by Anavex Life Sciences Corp, as the lead site for its upcoming Phase 2a trial for ANAVEX 2-73, which is being developed as a potential disease-modifying treatment for Alzheimer's disease. The trial will involve 32 patients with mild to moderate Alzheimer's disease, and is expected to last for a 6-months during which time tolerated dose and relationship between dose and efficacy outcomes will be measured through MMSE, ADSC-ADL, computerized cognitive tests and electroencephalography/event-related potentials (EEG/ERP).
"After a thorough review process including many international sites, we are very excited to be working with The Alfred Hospital, a world-renowned institution with significant experience in conducting Alzheimer's clinical trials," said Ananvex President and Chief Executive Officer Christopher U. Missling PhD. "The current Phase 2a trial is designed to be extremely efficient and embraces both adaptive trial features as well as population pharmacokinetics. This will enable the trial to determine the ANAVEX 2-73 dose and schedule that may provide the best therapeutic response with the least toxicity. We expect that positive results from the trial will provide a value inflection point for the Company and validate our drug candidates as a potentially effective treatments for Alzheimer's disease and other neurological disorders."
According to lead investigator Dr. Stephen Macfarlane, FRANZCP, Associate Professor and Director of Aged Psychiatry at The Alfred Hospital, "ANAVEX 2-73 (which is adminsteed orally) is a potentially promising new treatment for Alzheimer's
disease.A therapeutic that is safe and could be an add-on therapy to standard of care (donepezil) would obviously be a big step forward, given the currently limited treatment options in Alzheimer's disease."
McFarlane is also Chair of the Victorian Faculty of Old Age Psychiatry and Secretary of
the Binational faculty of Old Age Psychiatry within The Royal Australian and New Zealand College of Psychiatrists, and has become.renowned for his expertise in his field during a career spanning more than 25 years.
Founded in 1871, The Alfred Hospital has been recognized as a pacesetter in the Australian medical arena and has is a major tertiary referral teaching hospital. It
has a major role in the provision of specialist tertiary and quaternary services on a statewide and national basis. Specialist services include trauma services, emergency and intensive care, comprehensive cancer services, blood diseases, respiratory medicine, melanoma, bone marrow transplant, cardiology / cardiovascular services, neurosurgery, general and specialist surgery and medicine, psychiatry and diagnostic services.